Citadel Advisors
VTVT icon

Citadel Advisors’s vTv Therapeutics VTVT Stock Holding History

Citadel Advisors’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Buy
+5,906
New +$205K ﹤0.01% 11818
2023
Q2 		– Sell
-606
Closed -$19.6K – 15313
2023
Q1 		$19.6K Sell
606
-616
-50% -$20.9K ﹤0.01% 13082
2022
Q4 		$31.9K Buy
1,222
+397
+48% +$13.1K ﹤0.01% 12664
2022
Q3 		$32K Sell
825
-107
-11% -$4.21K ﹤0.01% 11875
2022
Q2 		$28K Buy
+932
New +$23.9K ﹤0.01% 12268
2022
Q1 		– Sell
-2,353
Closed -$94K – 14677
2021
Q4 		$94K Sell
2,353
-880
-27% -$47.2K ﹤0.01% 12780
2021
Q3 		$198K Buy
3,233
+37
+1% +$2.79K ﹤0.01% 11996
2021
Q2 		$291K Sell
3,196
-1,306
-29% -$132K ﹤0.01% 11347
2021
Q1 		$508K Buy
+4,502
New +$442K ﹤0.01% 9646
2020
Q4 		– Sell
-363
Closed -$26K – 11587
2020
Q3 		$26K Buy
+363
New +$31.9K ﹤0.01% 9806
2018
Q3 		– Sell
-265
Closed -$16K – 9734
2018
Q2 		$16K Buy
+265
New +$19.6K ﹤0.01% 8685
2016
Q1 		– Sell
-769
Closed -$209K – 8055
2015
Q4 		$209K Buy
769
+76
+11% +$21.3K ﹤0.01% 5751
2015
Q3 		$181K Buy
+693
New +$241K ﹤0.01% 6276

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's VTVT Position: Q2 2026 in Review

Citadel Advisors opened a new position in vTv Therapeutics (VTVT) in Q2 2026: 5,906 shares worth $222K. The stake represents ﹤0.01% of the portfolio and ranks #11818 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in VTVT as recently as Q1 2023.

Citadel Advisors first reported a position in VTVT in Q3 2015 and has held it in 13 quarters since. The position peaked at $508K in Q1 2021. 45 funds tracked by Wall St. Rank hold VTVT as of Q2 2026.

  • Citadel Advisors held 5,906 shares of vTv Therapeutics worth $222K as of Q2 2026.
  • vTv Therapeutics was a new Citadel Advisors position in Q2 2026.
  • vTv Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11818 holding.
  • Citadel Advisors first reported a position in vTv Therapeutics in Q3 2015 and has held it in 13 quarters since.
  • Citadel Advisors's vTv Therapeutics position peaked at $508K in Q1 2021.
  • 45 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.